Access to health
The diabetes epidemic affects today close to 371 million people according to IDF. It is estimated that within twenty years it will reach 552 million people. Most of these will be in developing countries. This situation calls for a concerted action to improve access to diabetes care in developing countries.
As a world leader in diabetes care, Novo Nordisk wants to ensure that more people with diabetes in developing countries have access to healthcare. The Novo Nordisk strategy for access to diabetes care is founded on our company's vision to defeat diabetes. It aims to improve the conditions for the next generations by protecting the most vulnerable and building partnerships and capacity to confront the diabetes epidemic in least developed countries and emerging economies.
For more information on our annual performance, see our Annual Report.
For more information about our latest activities, see our Reporting to UN Global Compact Communication on Progress.
For information about our programmes related to the access to health agenda, go to our website changingdiabetesaccess.com.
In addition Novo Nordisk has created the following organisations:
World Diabetes Foundation